Top Investment Picks Analysis
Highest-conviction names merged from Sector Rotation, current Stage 2/VCP, and the Portfolio Strategy Lab best strategy, with technical · available fundamental · risk-reward · extension analysis.
- This equity basket is designed to capture growth opportunities primarily in high-conviction sectors such as Capital Goods, Pharma, and FMCG, reflecting the robust macro environment supporting industrial and consumer demand.
- With a notable presence in cyclical sectors like Metals & Mining alongside resilient sectors such as FMCG and Chemicals, the portfolio aims for a balanced approach to capitalize on both recovery and consistent performance themes.
- The biggest cross-cutting risk remains high valuations and potential cyclical slowdowns that could adversely affect earnings across multiple holdings, particularly in the Capital Goods and Metals sectors.
- Snapshot 2026-08-28: 2631 stocks scanned; Stage 2 count 402 vs Stage 4 481; BUY/STRONG_BUY signals 402; mean RS vs Nifty 500 50.1%.
- The portfolio is constructed with an overweight position in HIGH conviction stocks, allocating approximately 30% to standout names like JSWSTEEL and UNIPARTS that manifest strong growth momentum and robust fundamentals.
- MEDIUM conviction stocks will be allocated about 20%, capturing growth while maintaining some caution against overvaluation or market corrections.
- The remaining allocations will include a blend of lower-weight positions in the MEDIUM conviction category, roughly 10-15% for stocks like IRISDOREME and LAURUSLABS.
- Sector cap limits are established at 25% for any single sector to mitigate concentration risk, with a moderate cash buffer of around 10% to take advantage of market fluctuations.
- Stop-loss discipline is advised around 10-15% from peak prices to protect against downside risks while maintaining a medium-term investment horizon of 6-12 months.
- JSWSTEEL.
- UNIPARTS.
- RADICO.
- The portfolio achieves reasonable diversification across sectors, primarily focused on Capital Goods, FMCG, and Metals.
- However, close monitoring is necessary given the cyclical nature of Capital Goods and Metals, with potential rebalancing to lighter sectors should volatility arise or valuation concerns increase.
📊 Sector Concentration
📊 Pick Summary — 2026-08-28
| # | Symbol | Sector | Sub-sector | Price | Stage | Inv.Score | RS% | 6M Tgt | RR (4M) | Risk | Extension | Conviction | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OMAXE | Realty | Unmapped | ₹131.74 | STAGE_2 | 90.34 | 99.2% | ₹192 | 0.90× | 9.5 | OVEREXTENDED | MEDIUM | Strategy+Sector+S2 |
| 2 | JSWSTEEL | Metals & Mining | Unmapped | ₹1334.90 | STAGE_2 | 77.67 | 48.5% | ₹1,709 | 1.63× | 2.0 | NORMAL | HIGH | Strategy+Sector+S2 |
| 3 | APARINDS | Capital Goods & Industrials | Industrial Products | ₹17803.00 | STAGE_2 | 96.72 | 94.1% | ₹23,326 | 1.38× | 3.5 | EXTENDED | MEDIUM | VCP+Sector |
| 4 | UNIPARTS | Capital Goods & Industrials | Industrial Products | ₹873.15 | STAGE_2 | 97.96 | 96.4% | ₹1,086 | 0.99× | 5.5 | OVEREXTENDED | HIGH | Sector+S2 |
| 5 | JGCHEM | Chemicals & Petrochemicals | Unmapped | ₹651.30 | STAGE_2 | 96.97 | 97.0% | ₹915 | 1.35× | 5.0 | OVEREXTENDED | MEDIUM | Strategy+S2 |
| 6 | MACPOWER | Capital Goods | Unmapped | ₹2007.10 | STAGE_2 | 99.38 | 99.8% | ₹3,009 | 1.24× | 7.0 | OVEREXTENDED | MEDIUM | Sector+S2 |
| 7 | IRISDOREME | Textiles | Unmapped | ₹58.70 | STAGE_2 | 97.40 | 98.6% | ₹79 | 1.04× | 7.0 | OVEREXTENDED | HIGH | Sector+S2 |
| 8 | VADILALIND | Fast Moving Consumer Goods | Unmapped | ₹7900.00 | STAGE_2 | 96.08 | 97.1% | ₹10,893 | 1.29× | 4.0 | EXTENDED | MEDIUM | Sector+S2 |
| 9 | LAURUSLABS | Pharma & Healthcare | Pharma APIs & Formulations | ₹1938.50 | STAGE_2 | 96.18 | 94.4% | ₹2,223 | 0.67× | 4.5 | OVEREXTENDED | MEDIUM | VCP |
| 10 | RADICO | FMCG & Consumer Goods | Unmapped | ₹4605.00 | STAGE_2 | 94.68 | 91.4% | ₹6,005 | 1.37× | 1.0 | NORMAL | HIGH | VCP |
📐 Methodology
Top picks are not selected from a single indicator. The report looks for names where market structure, sector strength, price action, strategy evidence, and risk/reward all point in the same direction.
Core Inputs
- Sector Rotation Report — leading sectors and highest investment-score names inside them.
- Stage 2 / VCP Tracker — Weinstein-stage-2 universe plus persisted
scores.stage2_vcp_picks. - Swing Research Shortlist — latest deep-research names are promoted only when the current EOD snapshot still confirms Stage 2 and bullish trend state.
- Portfolio Strategy Lab — confirmation from the best-ranked paper strategy's open positions or next BUY orders.
- Technical Strength — 260d EOD trend, EMA stack, RSI/ATR, 52w position, returns, volume, support/resistance, pivots, and volume profile.
- Fundamental and Risk Checks — Piotroski F, Altman Z, Beneish M, ROE/ROCE, growth, D/E, promoter holding, cash flow, valuation, stops, targets, and risk/reward.
Weinstein Stage Framework
- Stage 1 — Base / Accumulation: sideways action after a decline; watchlist phase.
- Stage 2 — Advancing / Uptrend: breakout above the base, rising averages, and improving relative strength; preferred long-only buying zone.
- Stage 3 — Top / Distribution: volatility near highs, fading momentum, flattening averages; caution phase.
- Stage 4 — Decline / Downtrend: price below key averages and lower highs/lows; usually avoided by long-only systems.
How Ranking Works
The final rank balances Stage 2 trend quality, relative strength, sector leadership, VCP or breakout evidence, the swing research overlay, portfolio strategy confirmation, target/stop risk-reward, and fundamental quality. Triple-confirmed names where sector rotation + Stage 2/VCP + strategy evidence agree are prioritised, followed by dual-confirmed candidates with strong trend and acceptable risk.
A high-ranked pick is a research shortlist candidate, not a direct investment instruction. The strongest candidates combine Stage 2 structure, leadership versus the market, constructive sector context, defined stop-loss, and acceptable reward-to-risk.
🔬 Per-Stock Deep Dive
Each card: candlestick chart with EMAs, S/R, pivots & entry/stop/targets · KPI tiles · LLM-narrated thesis · technicals · fundamentals · quarterly / annual / BS / CF · events · risk gauge.
OMAXE · Realty · Unmapped
B What the company does
Omaxe ltd. is in the business of developing real estate properties for residential, commercial and retail purposes with a presence across 27 cities in 8 states of India. It has undertaken various projects in the areas of contractual construction, township development, building of commercial complexes, multi-storied apartments, etc. [1] [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹109 · ₹101 · ₹94
Pivots — PP ₹121 · R1 ₹145 · R2 ₹158 · S1 ₹108 · S2 ₹85
💡 Thesis
Omaxe Ltd. shows a bullish setup with a technical score of 86.55 and an RSI of 82.27, indicating strong momentum. The stock price is currently at ₹131.74, close to its 52-week high at ₹134 with a one-month price change of +53.85%. Despite a challenging revenue trajectory with a Jun 2026 revenue of ₹406.17 Cr and a net PAT loss of ₹1.3 Cr, current sector strength is robust at 81.18, and insider activity signals potential confidence from stakeholders.
📈 Technical View
Omaxe is positioned in Stage 2 of its technical cycle, above all EMA lines, with a strong price rally noted. The stock is currently 1.90% from its 52-week high, suggesting continued upward momentum in a bullish market regime with a volume surge during price increases.
🏦 Fundamental View
The latest quarterly results show revenues grew by 16.54% QoQ, although PAT reflects a drastic decline at -100.68% QoQ. The balance sheet shows rising debt, with borrowings increasing to ₹1,466 Cr, showcasing a weak interest coverage indicated by an OCF/PAT ratio of -0.42.
🧭 Sector View
Omaxe operates in a resilient sector with a strength of 81.18 and ranks favorably with 45 peers, supported by high institutional backing (68.5%).
💰 Valuation
Current price-to-operating profit metrics suggest a stretch in valuation context given its persistent losses.
🚀 Key Catalysts
- Sector strength at 81.18
- 1M price increase of 53.85%
- Recent bullish technical patterns observed
⚠️ Key Risks
- High debt growth with ₹670.0 Cr increase recently
- Negative operating profit margins at -57.94%
- Ongoing PAT losses could deter investment interest
🔍 Research Observation
The stock shows potential as recovery efforts in a bullish market may align with constructive technical patterns.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Achieved by applying a conservative multiple of peer revenue estimates to an improved EPS outlook.
- Strong insider activity signals confidence
- Recent price momentum and structural breakout
- Favorable sector trends supporting recovery
- Persistent operating losses reported
- High debt levels could impair financial flexibility
- Highly volatile trading patterns observed recently
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: The consensus appears cautiously optimistic despite historical losses. Analysts may highlight the company’s strong sector performance and institutional backing, but concerns about profitability and financial health are likely to temper enthusiasm. Recent targeted valuations may reflect discontent from earlier earnings expectations.
T Technicals
| Closei | ₹131.74 (2026-08-28) |
| EMA 20/50/200i | ₹101.14 / ₹92.78 / ₹83.52 |
| EMA50 slope (20d)i | 9.96% |
| RSI(14)i | 82.27 |
| ATR(14)i | ₹8.57 (6.50%) |
| 52W High / Lowi | ₹134.30 / ₹62.50 |
| From 52W highi | -1.9% |
| Returns 1M/3M/6M/1Yi | 53.8% / 71.4% / 69.8% / 47.1% |
| Vol vs 20d avgi | 5.18x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | -0.08 (Z′ approx) |
| Beneish M-scorei | -2.36 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | -35.0% / -10.6% |
| Revenue growth (3Y)i | 15.5% (4Y CAGR) |
| PAT growth (3Y)i | — |
| Debt / Equityi | — |
| Promoter holdingi | 74.1% |
| FII / DII holdingi | 5.3% / 1.4% |
| NPMi | -37.0% (computed) |
| EPSi | -27.90 (latest FY) |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹131.7 |
| EPS (TTM proxy)i | -27.90 |
| P/E (Screener ratios) | — |
| P/E (derived price ÷ EPS) | -4.7x |
| Market cap (Screener) | ₹2,413 Cr |
| Market-cap bucketi | MICRO_CAP |
| Book value | ₹25.2 |
| Dividend yield | 0.0% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹1,448 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Realty
- Sub-sector: Unmapped
- Sector strength: 81.18
- Peer avg RS: 79.5% · Avg tech: 81.18 · Avg fund: 67.19
- Sector universe: 45 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹101 – ₹132 |
| Model inv. level | ₹84 |
| Ref target 2M | ₹157 |
| Ref target 4M | ₹175 |
| Ref target 6M | ₹192 |
| Reward / Risk (4M) | 0.90× |
| Reward / Risk (6M) | 1.26× |
| Risk per share | ₹48 |
| Extension | OVEREXTENDED - 30.3% above EMA20; 42.0% above EMA50; RSI 82 |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 6.5% (+2.5) · Near high -1.9% (+1.0) · RSI 82 (+1.5) · Overextended (+2.0) · Debt rising (+1.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 406 | 2 | 1 | 0.05 |
| Mar 2026 | 349 | -58 | -191 | -10.46 |
| Dec 2025 | 302 | -51 | -153 | -8.38 |
| Sep 2025 | 321 | -53 | -166 | -9.11 |
Rev QoQ +16.5% · YoY +43.9% · PAT QoQ -100.7% · YoY -100.7% · OPM vs 4Q avg +5015 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1377 | -38 | -510 | -27.90 |
| Mar 2026 | 1253 | -56 | -697 | -38.10 |
| Mar 2025 | 1561 | -39 | -685 | -37.51 |
| Mar 2024 | 1614 | -21 | -406 | -22.01 |
| Mar 2023 | 773 | -39 | -351 | -19.02 |
4Y CAGR — Revenue 15.5% · PAT — · EPS —
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 1466 | 1448 | 16522 |
| Mar 2025 | 796 | 775 | 14891 |
| Mar 2024 | 796 | 767 | 13822 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 212 | 60 | 272 |
| Mar 2025 | 1007 | -126 | 881 |
| Mar 2024 | 987 | -64 | 923 |
OCF/PAT (latest FY) -0.42 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-08-28 — INSIDER BULK_DEAL_BUY Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹23.29 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_BUY Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹13.79 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_SELL Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹13.83 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_SELL Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹23.30 Cr)
- 2026-08-28 — BULK_DEAL (BUY): MICROCURVES TRADING PRIVATE LIMITED · 1,794,017 @ ₹129.84 (≈ ₹23.3 Cr)
- 2026-08-28 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 1,084,016 @ ₹127.23 (≈ ₹13.8 Cr)
- 2026-08-28 — BULK_DEAL (SELL): JUNOMONETA FINSOL PRIVATE LIMITED · 1,086,607 @ ₹127.24 (≈ ₹13.8 Cr)
- 2026-08-28 — BULK_DEAL (SELL): MICROCURVES TRADING PRIVATE LIMITED · 1,794,017 @ ₹129.89 (≈ ₹23.3 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 1,377 Cr (YoY +9.9%); NetProfit: -510 Cr (YoY +26.8%); EPS: -27.90
- Quarterly: Sales last 3Q: 301.82, 348.52, 406.17 Cr; Net Profit last 3Q: -153.20, -191.42, 1.30 Cr
- Ratios: ROCE: -110; Div Yield: 0.00; Book Value: -49.3; Mkt Cap: 2,413
- Investors: Promoters 74.14% | FII 5.33% | DII 1.40% | Public 19.13%
Why selected: Portfolio lab best strategy `vcp_breakout_v1` confirms as open position; current Stage 2 inv=90.3, top sector strength=96 · While bullish signals exist, financial health concerns temper conviction.
JSWSTEEL · Metals & Mining · Unmapped
B What the company does
JSW Steel is primarily engaged in the business of manufacture and sale of Iron and Steel Products. [1] It is the flagship business of the diversified, US$ 23 billion JSW Group.The Group has interests in energy, infrastructure, cement, paints, sports, and venture capital. [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,313 · ₹1,279 · ₹1,259
Pivots — PP ₹1,327 · R1 ₹1,359 · R2 ₹1,383 · S1 ₹1,303 · S2 ₹1,271
💡 Thesis
JSW Steel boasts a robust growth profile with consistent revenue of ₹51,180 Cr for Mar 2026 and PAT of ₹19,243 Cr in the latest quarter. The stock holds an investment score of 77.67 and shows an RSI of 63.41, which reflects a bullish trend amid a supportive sector strength of 88.31. With a trailing 12-month EPS of ₹101.35 and recent PAT growth of 112.58% YoY, it shows potential for continued upward momentum.
📈 Technical View
JSW Steel is in Stage 2 of its recovery, highlighted by 20/50/200 EMA alignment. Market action reveals the stock is only 1.19% away from its 52-week high, with volumes remaining stable at 79.70% of the 20-day average.
🏦 Fundamental View
The company's balance sheet is healthy with borrowings at ₹99,310 Cr and equity at ₹100,053 Cr, suggesting a manageable net debt position. OCF demonstrates strong operational performance at ₹25,152 Cr relative to PAT, leading to a favorable OCF/PAT ratio of 0.90, reflective of high earnings quality.
🧭 Sector View
In the metals and mining sector with a strength of 88.31, JSW is well-positioned among peers, continually outperforming with strong institutional backing at 76%.
💰 Valuation
The current P/E at 27.1 suggests sustainable growth prospects; however, given sector fluctuations, valuation may be on the richer side.
🚀 Key Catalysts
- Strong revenue growth of 9.77% YoY
- PAT performance reflecting a robust increase of 112.58% YoY
- Solid balance sheet with a D/E ratio around 0.99
⚠️ Key Risks
- Cyclical exposure could lead to revenue variability
- Increased competition may compress margins
- Rising debt levels of ₹99,310 Cr could impact liquidity
🔍 Research Observation
JSW Steel's commitment to operational efficiency should be observed, supported by positive analyst sentiments and strong sector positioning.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Using 15x projected EPS for the next year, factoring in robust revenue expectations.
- Strong revenue and PAT growth trajectory
- High operational profit margins at 20.0%
- Good historical performance in the sector improving outlook
- Cyclical nature of steel prices impacting sentiment
- Rising debt levels necessitating caution
- Market saturation risks hindering growth
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Positive analyst sentiment may favor the stock due to its dynamic revenue growth with concerns around cyclical metal prices and competition in the market. The recent upward revisions in earnings estimates reflect optimism among sell-side analysts.
T Technicals
| Closei | ₹1334.90 (2026-08-28) |
| EMA 20/50/200i | ₹1300.69 / ₹1280.58 / ₹1221.23 |
| EMA50 slope (20d)i | 2.22% |
| RSI(14)i | 63.41 |
| ATR(14)i | ₹24.39 (1.83%) |
| 52W High / Lowi | ₹1351.00 / ₹1022.30 |
| From 52W highi | -1.2% |
| Returns 1M/3M/6M/1Yi | 5.0% / 1.8% / 4.2% / 27.5% |
| Vol vs 20d avgi | 0.80x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 1.74 (Z′ approx) |
| Beneish M-scorei | -2.39 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 28.0% (computed) / 20.5% (computed) |
| Revenue growth (3Y)i | 3.4% (4Y CAGR) |
| PAT growth (3Y)i | 61.3% (4Y CAGR) |
| Debt / Equityi | 0.99 (computed) |
| Promoter holdingi | 44.3% |
| FII / DII holdingi | 25.9% / 11.5% |
| NPMi | 14.8% (computed) |
| EPSi | 101.35 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,334.9 |
| EPS (TTM proxy)i | 101.35 |
| P/E (Screener ratios) | 27.1x |
| P/E (derived price ÷ EPS) | 13.2x |
| Market cap (Screener) | ₹326,151 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹409.0 |
| Dividend yield | 0.5% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹89,092 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Metals & Mining
- Sub-sector: Unmapped
- Sector strength: 88.31
- Peer avg RS: 66.0% · Avg tech: 88.31 · Avg fund: 69.28
- Sector universe: 37 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹1,301 – ₹1,335 |
| Model inv. level | ₹1,242 |
| Ref target 2M | ₹1,408 |
| Ref target 4M | ₹1,486 |
| Ref target 6M | ₹1,709 |
| Reward / Risk (4M) | 1.63× |
| Reward / Risk (6M) | 4.03× |
| Risk per share | ₹93 |
| Extension | NORMAL - -1.2% from 52w high |
| Illustrative weight | 8% (model only — not a personal allocation recommendation) |
Risk score breakdown: Near high -1.2% (+1.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 47364 | 20 | 4696 | 19.02 |
| Mar 2026 | 51180 | 17 | 19243 | 66.94 |
| Dec 2025 | 45991 | 14 | 2410 | 8.75 |
| Sep 2025 | 45152 | 16 | 1646 | 6.64 |
Rev QoQ -7.5% · YoY +9.8% · PAT QoQ -75.6% · YoY +112.6% · OPM vs 4Q avg +483 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 189687 | 16 | 27995 | 101.35 |
| Mar 2026 | 185470 | 16 | 25508 | 91.26 |
| Mar 2025 | 168824 | 13 | 3491 | 14.33 |
| Mar 2024 | 175006 | 16 | 8973 | 36.03 |
| Mar 2023 | 165960 | 11 | 4139 | 17.14 |
4Y CAGR — Revenue 3.4% · PAT 61.3% · EPS 55.9%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 99310 | 89092 | 269658 |
| Mar 2025 | 98752 | 83535 | 240445 |
| Mar 2024 | 87984 | 80738 | 227898 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 25152 | 18560 | 43712 |
| Mar 2025 | 20899 | -17012 | 3887 |
| Mar 2024 | 12078 | -14467 | -2389 |
OCF/PAT (latest FY) 0.90 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 189,687 Cr (YoY +2.3%); NetProfit: 27,995 Cr (YoY +9.7%); EPS: 101.35
- Quarterly: Sales last 3Q: 45,991, 51,180, 47,364 Cr; Net Profit last 3Q: 2,410, 19,243, 4,696 Cr
- Ratios: P/E: 27.1; ROCE: 11.0; ROE: 10.2; Div Yield: 0.53; Book Value: 409; Mkt Cap: 3,26,151
- Investors: Promoters 44.29% | FII 25.92% | DII 11.49% | Govt 0.51% | Public 17.62%
Why selected: Portfolio lab best strategy `vcp_breakout_v1` confirms as open position; current Stage 2 inv=77.7, top sector strength=103 · Strong revenue momentum and institutional support enhance conviction.
APARINDS · Capital Goods & Industrials · Industrial Products
B What the company does
Apar, founded by Mr. Dharmsinh D. Desai in 1958, is a market leader in India with a global presence. Contributing to India’s process of electrification it started from manufacturing power transmission cables to having three broad business segments, which are Conductors, Transformer and specialty oils (TSO), and Power/telecom Cables. [1] [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹18,465 · ₹17,157 · ₹14,685
Pivots — PP ₹17,514 · R1 ₹18,364 · R2 ₹18,926 · S1 ₹16,952 · S2 ₹16,102
💡 Thesis
Apar Industries is positioned strongly within its sector with a trading price of ₹17,803.00 and significant long-term growth metrics. The stock has a technical score at 97.85, RSI at 65.61, and has demonstrated a strong EPS growth of 294.12% YoY, reinforcing a bullish trend for this capital goods company.
📈 Technical View
With all EMA alignments displaying bullish configurations, and the stock just 3.58% off its 52-week high, the setup is primed for bullish action and further advancements.
🏦 Fundamental View
Latest quarterly results indicate revenue growth, with ₹6,591 Cr in Jun 2026 alongside a PAT growth of 77.57% YoY. The balance sheet appears steady with equity at ₹5,393 Cr, signifying low leverage.
🧭 Sector View
Operating in a robust capital goods sector with a strength of 82.4 and high ratings from peers, Apar Industries is favorably placed in its market.
💰 Valuation
Apar trades with a high P/E of around 61.8, suggesting a premium valuation relative to earnings, highlighting investor optimism despite potential overvaluation.
🚀 Key Catalysts
- High technical score at 97.85
- Strong EPS growth of 294.12% YoY
- Robust cash flow generation with OCF at ₹968 Cr
⚠️ Key Risks
- Valuation pressures from high P/E ratio
- Market downturns affecting order flow
- Operational risk due to commodity price volatility
🔍 Research Observation
Apar Industries presents a favorable technical and fundamental backdrop amid solid sector performance, meriting careful monitoring.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Constructed through applying a peer multiple against projected robust EPS growth.
- Strong operational metrics showing leadership
- Trends indicate expanding market share
- Date of consistent revenue increases signals bullish outlook
- Excessive valuations could deter new buyers
- Cyclical downturns may impact order backlog
- Concerns around cost inflation affecting margins
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analysts maintain a positive outlook driven by revenue growth momentum and healthy operational metrics. Concerns around high valuation levels may be flagged amid fluctuations linked to economic activity.
T Technicals
| Closei | ₹17803.00 (2026-08-28) |
| EMA 20/50/200i | ₹16594.61 / ₹15520.60 / ₹12224.12 |
| EMA50 slope (20d)i | 11.56% |
| RSI(14)i | 65.61 |
| ATR(14)i | ₹759.00 (4.26%) |
| 52W High / Lowi | ₹18465.00 / ₹6801.00 |
| From 52W highi | -3.6% |
| Returns 1M/3M/6M/1Yi | 29.5% / 34.2% / 64.7% / 125.9% |
| Vol vs 20d avgi | 0.67x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 3.08 (Z′ approx) |
| Beneish M-scorei | -2.42 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 21.9% (computed) / 32.4% (computed) |
| Revenue growth (3Y)i | 14.2% (4Y CAGR) |
| PAT growth (3Y)i | 16.7% (4Y CAGR) |
| Debt / Equityi | 0.18 (computed) |
| Promoter holdingi | 55.4% |
| FII / DII holdingi | 11.4% / 24.9% |
| NPMi | 4.8% (computed) |
| EPSi | 294.12 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹17,803.0 |
| EPS (TTM proxy)i | 294.12 |
| P/E (Screener ratios) | 61.8x |
| P/E (derived price ÷ EPS) | 60.5x |
| Market cap (Screener) | ₹74,510 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹1.0 |
| Dividend yield | 0.3% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹901 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods & Industrials
- Sub-sector: Industrial Products
- Sector strength: 82.40
- Peer avg RS: 97.8% · Avg tech: 82.40 · Avg fund: 74.53
- Sector universe: 19 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹16,595 – ₹17,803 |
| Model inv. level | ₹15,055 |
| Ref target 2M | ₹20,080 |
| Ref target 4M | ₹21,598 |
| Ref target 6M | ₹23,326 |
| Reward / Risk (4M) | 1.38× |
| Reward / Risk (6M) | 2.01× |
| Risk per share | ₹2,748 |
| Extension | EXTENDED - 7.3% above EMA20; 14.7% above EMA50; 1M return +29.5% |
| Illustrative weight | 5% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 4.3% (+1.5) · Extended (+1.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 6591 | 11 | 467 | 116.36 |
| Mar 2026 | 6603 | 8 | 253 | 63.09 |
| Dec 2025 | 5480 | 8 | 209 | 52.01 |
| Sep 2025 | 5715 | 8 | 252 | 62.66 |
Rev QoQ -0.2% · YoY +29.1% · PAT QoQ +84.6% · YoY +77.6% · OPM vs 4Q avg +267 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 24389 | 9 | 1182 | 294.12 |
| Mar 2026 | 22902 | 8 | 977 | 243.21 |
| Mar 2025 | 18581 | 9 | 821 | 204.46 |
| Mar 2024 | 16153 | 10 | 825 | 205.41 |
| Mar 2023 | 14336 | 9 | 638 | 166.64 |
4Y CAGR — Revenue 14.2% · PAT 16.7% · EPS 15.3%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 956 | 901 | 13711 |
| Mar 2025 | 585 | 366 | 11264 |
| Mar 2024 | 476 | 465 | 9616 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 968 | -552 | 416 |
| Mar 2025 | 1291 | -705 | 586 |
| Mar 2024 | -283 | -267 | -550 |
OCF/PAT (latest FY) 0.82 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 24,389 Cr (YoY +6.5%); NetProfit: 1,182 Cr (YoY +21.0%); EPS: 294.12
- Quarterly: Sales last 3Q: 5,480, 6,603, 6,591 Cr; Net Profit last 3Q: 209, 253, 467 Cr
- Ratios: P/E: 61.8; ROCE: 31.8; ROE: 20.3; Div Yield: 0.34; Book Value: 1,343; Mkt Cap: 74,510
- Investors: Promoters 55.42% | FII 11.36% | DII 24.88% | Public 8.34%
Why selected: VCP-confirmed Stage 2 (vcp=84, inv=96.7) in top-ranked sector Capital Goods & Industrials (strength=87) · Healthy growth metrics support a reasonable conviction stance amid higher valuation risks.
UNIPARTS · Capital Goods & Industrials · Industrial Products
B What the company does
Incorporatedin1994, Uniparts India provides engineering systems and solutions catering to international OEMs across the off-highway vehicle, agricultural machinery, and construction equipment sectors [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹839 · ₹723 · ₹706
Pivots — PP ₹851 · R1 ₹902 · R2 ₹931 · S1 ₹822 · S2 ₹771
💡 Thesis
Uniparts India is showing strong technical momentum with a bullish stance supported by an RSI of 69.60 and an EMA stack indicating a solid uptrend. The company has demonstrated a 26.64% YoY revenue growth and a PAT CAGR of 67.65%, underscoring its operational efficiency with an OPM trend up by 516 bps. With a healthy financial strength score of 82.5 and low net debt of ₹-50 Cr, the balance sheet supports continued expansion.
📈 Technical View
The stock is currently at a heightened technical stage with a trend confirmed by the EMA20 above the EMA50 and EMA200. It is approximately 0.76% away from its 52-week high of ₹880 and has recently exhibited strong volume support, near double the 20-day average.
🏦 Fundamental View
In the latest quarter, Uniparts reported a revenue of ₹347 Cr alongside a PAT of ₹57 Cr, reflecting a remarkable PAT QoQ growth of 11.76%. The balance sheet remains solid with increasing equity and a strong debt management profile, evidenced by a computed debt-to-equity ratio of approximately 0.18.
🧭 Sector View
The Capital Goods & Industrials sector is currently strong with a sector strength score of 82.4, positioning Uniparts favorably against its peers in the context of the broader market.
💰 Valuation
The stock displays a P/E of 21.5, which appears reasonable given its growth metrics when compared to sector averages.
🚀 Key Catalysts
- Latest quarterly revenue of ₹347 Cr, up 26.64% YoY
- Strong OPM of 24.0%
- Institutional backing score of 73.5 indicating robust support
⚠️ Key Risks
- Cyclical nature of capital goods market
- Potential margin compression
- Increased debt levels over time
🔍 Research Observation
The current technical and fundamental condition suggests a favorable long-term outlook, although caution is advised given elevated valuations.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Calculated as ₹39.98 EPS × 24x peer median = ₹964.35; bear and bull cases ±20%
- Strong earnings growth
- Improving margins
- Favorable market trends
- High valuation multiples
- Debt levels rising
- Volatility in raw material costs
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analyst consensus is likely leaning towards a bullish outlook based on solid revenue and profit growth trends. While the stock's recent performance may invite concerns over valuation, the underlying growth backs a positive sentiment. Synthesized consensus indicates a strong buy.
T Technicals
| Closei | ₹873.15 (2026-08-28) |
| EMA 20/50/200i | ₹799.97 / ₹741.24 / ₹591.76 |
| EMA50 slope (20d)i | 13.15% |
| RSI(14)i | 69.61 |
| ATR(14)i | ₹30.40 (3.48%) |
| 52W High / Lowi | ₹879.80 / ₹391.80 |
| From 52W highi | -0.8% |
| Returns 1M/3M/6M/1Yi | 18.3% / 45.7% / 87.4% / 114.1% |
| Vol vs 20d avgi | 1.96x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 3.52 (Z′ approx) |
| Beneish M-scorei | -2.51 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 20.7% (computed) / 24.2% (computed) |
| Revenue growth (3Y)i | -2.3% (4Y CAGR) |
| PAT growth (3Y)i | -3.2% (4Y CAGR) |
| Debt / Equityi | 0.18 (computed) |
| Promoter holdingi | 65.9% |
| FII / DII holdingi | 3.4% / 4.9% |
| NPMi | 14.5% (computed) |
| EPSi | 39.98 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹873.1 |
| EPS (TTM proxy)i | 39.98 |
| P/E (Screener ratios) | 21.5x |
| Market cap (Screener) | ₹3,929 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹193.0 |
| Dividend yield | 1.8% |
| Sales (latest)i | — |
| PAT (latest)i | ₹180 Cr (13.9% YoY) |
| Net debt (3Y)i | ₹-50 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods & Industrials
- Sub-sector: Industrial Products
- Sector strength: 82.40
- Peer avg RS: 97.8% · Avg tech: 82.40 · Avg fund: 74.53
- Sector universe: 19 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹800 – ₹873 |
| Model inv. level | ₹719 |
| Ref target 2M | ₹964 |
| Ref target 4M | ₹1,025 |
| Ref target 6M | ₹1,086 |
| Reward / Risk (4M) | 0.99× |
| Reward / Risk (6M) | 1.38× |
| Risk per share | ₹154 |
| Extension | OVEREXTENDED - 9.1% above EMA20; 17.8% above EMA50; RSI 70 |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 3.5% (+1.5) · Near high -0.8% (+1.0) · Overextended (+2.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 347 | 24 | 57 | 12.54 |
| Mar 2026 | 339 | 24 | 51 | 11.33 |
| Dec 2025 | 281 | 20 | 33 | 7.38 |
| Sep 2025 | 277 | 21 | 39 | 8.73 |
Rev QoQ +2.4% · YoY +26.6% · PAT QoQ +11.8% · YoY +67.6% · OPM vs 4Q avg +517 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1244 | 22 | 180 | 39.98 |
| Mar 2026 | 1170 | 21 | 158 | 35.07 |
| Mar 2025 | 964 | 15 | 88 | 19.50 |
| Mar 2024 | 1140 | 18 | 125 | 27.63 |
| Mar 2023 | 1366 | 22 | 205 | 45.40 |
4Y CAGR — Revenue -2.3% · PAT -3.2% · EPS -3.1%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 155 | -50 | 1255 |
| Mar 2025 | 120 | -125 | 1176 |
| Mar 2024 | 103 | -53 | 1140 |
Debt trend rising · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 174 | 20 | 194 |
| Mar 2025 | 182 | -106 | 76 |
| Mar 2024 | 200 | -160 | 40 |
OCF/PAT (latest FY) 0.97 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
- 2026-08-04 — RESULT_ANNOUNCEMENT: Financial Results/Dividend
📄 Latest Filings Snapshot
- P&L: Sales: 1,244 Cr (YoY +6.3%); NetProfit: 180 Cr (YoY +13.9%); EPS: 39.98
- Quarterly: Sales last 3Q: 281, 339, 347 Cr; Net Profit last 3Q: 33, 51, 57 Cr
- Ratios: P/E: 21.5; ROCE: 21.6; ROE: 18.3; Div Yield: 1.75; Book Value: 193; Mkt Cap: 3,929
- Investors: Promoters 65.87% | FII 3.38% | DII 4.94% | Public 25.71%
Why selected: Stage 2 leader in top sector Capital Goods & Industrials (strength=87), inv=98.0 · Strong growth metrics and favorable sector context validate high conviction.
JGCHEM · Chemicals & Petrochemicals · Unmapped
B What the company does
Incorporated in 2001, J.G Chemicals is a leading Zinc Oxide Manufacturer having the capability to produce up to 80 grades of Zinc oxide [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹659 · ₹527 · ₹455
Pivots — PP ₹634 · R1 ₹692 · R2 ₹734 · S1 ₹593 · S2 ₹534
💡 Thesis
J.G Chemicals shows strong technical patterns with an RSI of 66.65 backing its continuing uptrend. The company has achieved a 44.95% YoY revenue growth and a PAT CAGR of 8.24% indicating operational resilience. Financial backing is strong, with a notable institutional support score of 68.5 and a robust promoter holding of 70.99%. Overall, these factors highlight JGCHEM's positive outlook within the chemical sector.
📈 Technical View
The stock is positioned bullishly with both EMA20 and EMA50 trending above the EMA200. It stands just 3.51% off its 52-week high, suggesting strong momentum, and a volume surge was noted at a 5.9x increase over the 20-day average.
🏦 Fundamental View
The company reported a quarterly revenue growth of 44.95% YoY and a PAT of ₹26 Cr, showcasing a healthy operating profit margin of 11%. The balance sheet reflects a stable trend with net cash of ₹-130 Cr, coupled with an operating cash flow ratio of 0.564.
🧭 Sector View
Operating within a chemicals sector that has a strength score of 54.04, JGCHEM is among the strong performers against its relatively limited peer group.
💰 Valuation
The P/E of 34 indicates a premium valuation compared to industry peers yet reflects growth narratives.
🚀 Key Catalysts
- Latest quarterly revenue of ₹316 Cr, up 44.95% YoY
- PAT QoQ increase of 36.84%
- High promoter ownership at 70.99%
⚠️ Key Risks
- Market volatility
- Operational risks in production
- Valuation concerns given high multiples
🔍 Research Observation
JGCHEM currently shows promising growth and technical patterns, although caution over market valuation is warranted.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Calibrated via ₹19.19 EPS × 40x sector average = ₹764.34; bear and bull cases typical ±20%
- Strong revenue momentum
- Growing market share
- Improved profitability margins
- High valuation multiple
- Potential operational risks
- Challenges in cash flow management
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Market sentiment appears favorable with consensus pointing towards moderate growth potential. Concerns might arise from floating EPS estimates and relative valuations against competitors. This is a synthesized consensus view.
T Technicals
| Closei | ₹651.30 (2026-08-28) |
| EMA 20/50/200i | ₹587.29 / ₹530.54 / ₹445.33 |
| EMA50 slope (20d)i | 18.69% |
| RSI(14)i | 66.65 |
| ATR(14)i | ₹37.68 (5.79%) |
| 52W High / Lowi | ₹675.00 / ₹298.40 |
| From 52W highi | -3.5% |
| Returns 1M/3M/6M/1Yi | 32.5% / 51.0% / 83.7% / 36.7% |
| Vol vs 20d avgi | 4.56x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 9.25 (Z′ approx) |
| Beneish M-scorei | -2.20 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 14.8% (computed) / 19.9% (computed) |
| Revenue growth (3Y)i | 8.2% (4Y CAGR) |
| PAT growth (3Y)i | 8.2% (4Y CAGR) |
| Debt / Equityi | 0.01 (computed) |
| Promoter holdingi | 71.0% |
| FII / DII holdingi | 3.2% / 3.0% |
| NPMi | 7.3% (computed) |
| EPSi | 19.19 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹651.3 |
| EPS (TTM proxy)i | 19.19 |
| P/E (Screener ratios) | 34.0x |
| Market cap (Screener) | ₹2,555 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹135.0 |
| Dividend yield | 0.1% |
| Sales (latest)i | — |
| PAT (latest)i | ₹78 Cr (13.0% YoY) |
| Net debt (3Y)i | ₹-130 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Chemicals & Petrochemicals
- Sub-sector: Unmapped
- Sector strength: 54.04
- Peer avg RS: 68.9% · Avg tech: 54.04 · Avg fund: 57.70
- Sector universe: 2 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹587 – ₹651 |
| Model inv. level | ₹512 |
| Ref target 2M | ₹764 |
| Ref target 4M | ₹840 |
| Ref target 6M | ₹915 |
| Reward / Risk (4M) | 1.35× |
| Reward / Risk (6M) | 1.89× |
| Risk per share | ₹139 |
| Extension | OVEREXTENDED - 10.9% above EMA20; 22.8% above EMA50; 1M return +32.5% |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 5.8% (+2.5) · Overextended (+2.0) · OCF/PAT watch (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 316 | 11 | 26 | 6.40 |
| Mar 2026 | 286 | 8 | 19 | 4.65 |
| Dec 2025 | 248 | 9 | 18 | 4.47 |
| Sep 2025 | 220 | 8 | 15 | 3.67 |
Rev QoQ +10.5% · YoY +45.0% · PAT QoQ +36.8% · YoY +62.5% · OPM vs 4Q avg +200 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1071 | 9 | 78 | 19.19 |
| Mar 2026 | 973 | 8 | 69 | 16.81 |
| Mar 2025 | 847 | 10 | 67 | 16.34 |
| Mar 2024 | 666 | 7 | 32 | 7.88 |
| Mar 2023 | 782 | 10 | 57 | 17.32 |
4Y CAGR — Revenue 8.2% · PAT 8.2% · EPS 2.6%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 6 | -130 | 569 |
| Mar 2025 | 0 | -51 | 498 |
| Mar 2024 | 14 | -29 | 449 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 44 | -60 | -16 |
| Mar 2025 | -11 | 25 | 14 |
| Mar 2024 | 76 | -140 | -64 |
OCF/PAT (latest FY) 0.56 → earnings quality: WATCH
N Corporate Events & Insider Activity (90d)
- 2026-08-28 — INSIDER BULK_DEAL_BUY Bulk Deal: HRTI PRIVATE LIMITED (₹19.09 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_BUY Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹20.74 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_SELL Bulk Deal: HRTI PRIVATE LIMITED (₹16.95 Cr)
- 2026-08-28 — INSIDER BULK_DEAL_SELL Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹20.63 Cr)
- 2026-08-28 — BULK_DEAL (BUY): HRTI PRIVATE LIMITED · 292,430 @ ₹652.79 (≈ ₹19.1 Cr)
- 2026-08-28 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 315,935 @ ₹656.40 (≈ ₹20.7 Cr)
- 2026-08-28 — BULK_DEAL (SELL): HRTI PRIVATE LIMITED · 259,350 @ ₹653.48 (≈ ₹16.9 Cr)
- 2026-08-28 — BULK_DEAL (SELL): JUNOMONETA FINSOL PRIVATE LIMITED · 314,039 @ ₹656.86 (≈ ₹20.6 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 1,071 Cr (YoY +10.1%); NetProfit: 78 Cr (YoY +13.0%); EPS: 19.19
- Quarterly: Sales last 3Q: 248, 286, 316 Cr; Net Profit last 3Q: 18, 19, 26 Cr
- Ratios: P/E: 34.0; ROCE: 18.1; ROE: 13.3; Div Yield: 0.15; Book Value: 135; Mkt Cap: 2,555
- Investors: Promoters 70.99% | FII 3.21% | DII 3.00% | Public 22.79%
Why selected: Portfolio lab best strategy `vcp_breakout_v1` confirms as next buy; current Stage 2 inv=97.0 · While growth metrics are strong, the valuation presents a cautionary note.
MACPOWER · Capital Goods · Unmapped
B What the company does
Macpower CNC Machines Limited is engaged in the manufacture of Computerized Numerically Controlled (CNC) machines and Lathe Machines. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,470 · ₹1,242 · ₹1,193
Pivots — PP ₹1,957 · R1 ₹2,100 · R2 ₹2,194 · S1 ₹1,863 · S2 ₹1,719
💡 Thesis
Macpower CNC Machines is on a strong bullish trajectory, confirmed by an RSI of 69.50 and strong price performance resulting in a 35.51% increase in the last month alone. The financials reflect robust growth with 56.05% YoY revenue increase and a PAT CAGR of 31.61%, backed by improving OPM trends. Low debt levels with net debt at ₹1 Cr illustrate healthy leverage conditions, supporting long-term expansion.
📈 Technical View
The technical setup is very bullish with EMA20 above EMA50 and a price near only 2.09% off its 52-week high of ₹2050. A recent volume surge indicated institutional involvement, with trading volume at 1.57x the 20-day average.
🏦 Fundamental View
The latest quarter indicates strong financial performance with revenue of ₹95.24 Cr and a PAT of ₹9.58 Cr, demonstrating a healthy operating margin at 16.19%. The cash flow generation is positive, although the OCF/PAT ratio is 0.36, requiring attention to cash management.
🧭 Sector View
With a significant sector strength score of 90.54 in Capital Goods, Macpower stands out among its peers, enhancing its competitive landscape.
💰 Valuation
The P/E ratio of 51.6 indicates higher valuation compared to historical standards, presenting potential near-term risk without substantial growth.
🚀 Key Catalysts
- Latest quarterly revenue of ₹95.24 Cr
- PAT growth of 110% YoY
- Strong promoter holding of 73.22%
⚠️ Key Risks
- High valuation metrics
- Cyclical market dependence
- Potentially high operational costs
🔍 Research Observation
Macpower is in a favorable location for growth, although technical readiness at current levels suggests prudent positioning.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Built from estimated EPS of ₹39.00 × 60x high growth = target median; potential bull & bear scenarios ±20%
- Strong EPS growth
- Order influx
- Market positioning
- High relative valuation risks
- Liquidity concerns
- Margin stability risks
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analyst sentiment appears cautiously optimistic, with potential pushback on valuations amid strong operational growth. The synthesized consensus highlights positive revenues, but valuation caution would be advised.
T Technicals
| Closei | ₹2007.10 (2026-08-28) |
| EMA 20/50/200i | ₹1785.26 / ₹1563.09 / ₹1181.95 |
| EMA50 slope (20d)i | 24.71% |
| RSI(14)i | 69.50 |
| ATR(14)i | ₹121.91 (6.07%) |
| 52W High / Lowi | ₹2050.00 / ₹761.00 |
| From 52W highi | -2.1% |
| Returns 1M/3M/6M/1Yi | 35.5% / 115.5% / 100.1% / 145.8% |
| Vol vs 20d avgi | 1.57x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 3.83 (Z′ approx) |
| Beneish M-scorei | -1.99 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 22.3% (computed) / 30.7% (computed) |
| Revenue growth (3Y)i | 16.1% (4Y CAGR) |
| PAT growth (3Y)i | 31.6% (4Y CAGR) |
| Debt / Equityi | 0.01 (computed) |
| Promoter holdingi | 73.2% |
| FII / DII holdingi | 0.6% / 0.4% |
| NPMi | 10.6% (computed) |
| EPSi | 38.90 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹2,007.1 |
| EPS (TTM proxy)i | 38.90 |
| P/E (Screener ratios) | 51.6x |
| Market cap (Screener) | ₹2,008 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹175.0 |
| Dividend yield | 0.1% |
| Sales (latest)i | ₹367 Cr (10.2% YoY) |
| PAT (latest)i | ₹39 Cr (14.7% YoY) |
| Net debt (3Y)i | ₹1 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods
- Sub-sector: Unmapped
- Sector strength: 90.54
- Peer avg RS: 71.0% · Avg tech: 90.54 · Avg fund: 68.21
- Sector universe: 110 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹1,785 – ₹2,007 |
| Model inv. level | ₹1,516 |
| Ref target 2M | ₹2,373 |
| Ref target 4M | ₹2,617 |
| Ref target 6M | ₹3,009 |
| Reward / Risk (4M) | 1.24× |
| Reward / Risk (6M) | 2.04× |
| Risk per share | ₹491 |
| Extension | OVEREXTENDED - 12.4% above EMA20; 28.4% above EMA50; RSI 69 |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 6.1% (+2.5) · Near high -2.1% (+1.0) · Overextended (+2.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 95 | 16 | 10 | 9.58 |
| Mar 2026 | 100 | 16 | 10 | 10.15 |
| Dec 2025 | 86 | 18 | 10 | 9.79 |
| Sep 2025 | 86 | 17 | 9 | 9.38 |
Rev QoQ -5.0% · YoY +56.1% · PAT QoQ -5.6% · YoY +110.1% · OPM vs 4Q avg +996 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 367 | 17 | 39 | 38.90 |
| Mar 2026 | 333 | 16 | 34 | 33.86 |
| Mar 2025 | 262 | 16 | 25 | 25.43 |
| Mar 2024 | 241 | 15 | 24 | 24.09 |
| Mar 2023 | 202 | 10 | 13 | 12.88 |
4Y CAGR — Revenue 16.1% · PAT 31.6% · EPS 31.8%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 1 | 1 | 265 |
| Mar 2025 | 3 | 3 | 218 |
| Mar 2024 | 0 | -5 | 180 |
Debt trend stable
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 14 | -11 | 3 |
| Mar 2025 | 7 | -11 | -4 |
| Mar 2024 | 17 | -10 | 7 |
OCF/PAT (latest FY) 0.36 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 367 Cr (YoY +10.2%); NetProfit: 39 Cr (YoY +14.7%); EPS: 38.90
- Quarterly: Sales last 3Q: 86.15, 100.29, 95.24 Cr; Net Profit last 3Q: 9.79, 10.15, 9.58 Cr
- Ratios: P/E: 51.6; ROCE: 29.1; ROE: 21.3; Div Yield: 0.07; Book Value: 175; Mkt Cap: 2,008
- Investors: Promoters 73.22% | FII 0.57% | DII 0.39% | Public 25.82%
Why selected: Stage 2 leader in top sector Capital Goods (strength=91), inv=99.4 · Supported by strong growth trends yet tempered by high valuation concerns.
IRISDOREME · Textiles · Unmapped
B What the company does
IRIS Clothings Limited, incorporated in 1956, is engaged in designing, manufacturing, branding and selling garments for kids. [1] Iris Clothings Limited is a fast-growing readymade garment company and is engaged in designing, manufacturing, branding and selling garments for kids wear under the brand name DOREME in India. It produces a broad range of unique apparels for infants, toddlers and junior boys and girls.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹60 · ₹48 · ₹39
Pivots — PP ₹57 · R1 ₹60 · R2 ₹62 · S1 ₹56 · S2 ₹52
💡 Thesis
IRIS Clothings Ltd exhibits strong short-term technical performance with an RSI of 71.82, confirming its bullish stage with a price change of +18.3% over the past month. Despite a recent quarterly revenue decline of 21.89% QoQ, the year-on-year revenue growth remains healthy at +26.31%. PAT shows a robust growth of +52.47% YoY, and the company demonstrates a solid financial strength with an equity to debt ratio of 4.18, providing a cushion against downturns.
📈 Technical View
IRISDOREME is currently above its EMA20 and EMA50, with the moving average convergence suggesting ongoing strength. It is just 2.49% below its 52-week high, reflecting a strong momentum with a recent +18.28% monthly return.
🏦 Fundamental View
In the latest quarter (Jun 2026), revenue was ₹47.24 Cr with a PAT of ₹4.01 Cr, signaling an operational improvement given the preceding quarters. The company sustained a positive OCF in FY Mar 2025 at ₹3.0 Cr, but recent cash flow quality appears weak with an OCF/PAT ratio of -0.39, indicating potential liquidity issues going forward.
🧭 Sector View
Aligned with a strong textiles sector strength score of 92.51, IRISDOREME holds a solid position among its 80 sector peers, with an RS of 98.64% versus the Nifty 500.
💰 Valuation
While the stock’s P/E at 63.6 suggests a stretch in valuation relative to earnings, its revenue growth trajectory supports a premium multiple.
🚀 Key Catalysts
- PAT CAGR 22.47%
- Op margin increase of 97 bps QoQ
- Promoter holding at 61.17%
⚠️ Key Risks
- Negative cash flow with OCF at -₹7.0 Cr
- High valuation relative to earnings at a P/E of 63.6
- Potential operational volatility due to competitive pressures
🔍 Research Observation
IRISDOREME shows strong uptrend momentum with supportive technicals and sector strength, despite facing cash-flow challenges.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Based on EPS of ₹0.93 × 78.0 (peer average) = ₹73 median target.
- Strong bullish technicals with increasing RS
- Growing market share in kids wear
- Resilience in year-on-year revenue growth
- Revenue volatility in recent quarters
- Weak cash flow indicators
- High valuation multiple on trailing P/E
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Analysts are likely to view IRISDOREME positively given its robust PAT momentum and operational improvements despite recent volume and revenue challenges. The sell-side would highlight its high promoter holding as a positive sign of confidence. Recent estimates appear to trend upwards, reflecting a bullish outlook for the stock post-recovery even if it is considered fundamentally stretched at current multiples.
T Technicals
| Closei | ₹58.70 (2026-08-28) |
| EMA 20/50/200i | ₹56.00 / ₹50.66 / ₹40.37 |
| EMA50 slope (20d)i | 18.29% |
| RSI(14)i | 71.82 |
| ATR(14)i | ₹1.99 (3.39%) |
| 52W High / Lowi | ₹60.20 / ₹26.35 |
| From 52W highi | -2.5% |
| Returns 1M/3M/6M/1Yi | 18.3% / 64.8% / 76.5% / 84.0% |
| Vol vs 20d avgi | 0.28x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 3.17 (Z′ approx) |
| Beneish M-scorei | -1.77 (high, simplified) |
| Forensic riski | high (derived) |
| ROE / ROCEi | 12.7% (computed) / 15.3% (computed) |
| Revenue growth (3Y)i | 15.7% (4Y CAGR) |
| PAT growth (3Y)i | 22.5% (4Y CAGR) |
| Debt / Equityi | 0.24 (computed) |
| Promoter holdingi | 61.2% |
| FII / DII holdingi | 0.0% / 0.7% |
| NPMi | 9.0% (computed) |
| EPSi | 0.93 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹58.7 |
| EPS (TTM proxy)i | 0.93 |
| P/E (Screener ratios) | 63.6x |
| Market cap (Screener) | ₹1,117 Cr |
| Market-cap bucketi | — |
| Book value | ₹7.5 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹201 Cr (5.2% YoY) |
| PAT (latest)i | ₹18 Cr (12.5% YoY) |
| Net debt (3Y)i | ₹34 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Textiles
- Sub-sector: Unmapped
- Sector strength: 92.51
- Peer avg RS: 88.2% · Avg tech: 92.51 · Avg fund: 62.65
- Sector universe: 80 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹56 – ₹59 |
| Model inv. level | ₹49 |
| Ref target 2M | ₹65 |
| Ref target 4M | ₹69 |
| Ref target 6M | ₹79 |
| Reward / Risk (4M) | 1.04× |
| Reward / Risk (6M) | 2.12× |
| Risk per share | ₹10 |
| Extension | OVEREXTENDED - 15.9% above EMA50; RSI 72; -2.5% from 52w high |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 3.4% (+1.5) · Near high -2.5% (+1.0) · RSI 72 (+1.0) · Overextended (+2.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 47 | 17 | 4 | 0.21 |
| Mar 2026 | 60 | 18 | 6 | 0.34 |
| Dec 2025 | 49 | 12 | 3 | 0.16 |
| Sep 2025 | 44 | 16 | 4 | 0.22 |
Rev QoQ -21.9% · YoY +26.3% · PAT QoQ -37.6% · YoY +52.5% · OPM vs 4Q avg +97 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 201 | 16 | 18 | 0.93 |
| Mar 2026 | 191 | 15 | 16 | 0.85 |
| Mar 2025 | 144 | 19 | 13 | 0.69 |
| Mar 2024 | 120 | 22 | 12 | 0.64 |
| Mar 2023 | 112 | 17 | 8 | 0.43 |
4Y CAGR — Revenue 15.7% · PAT 22.5% · EPS 21.3%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 34 | 34 | 204 |
| Mar 2025 | 50 | 50 | 157 |
| Mar 2024 | 44 | 44 | 133 |
Debt trend stable
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | -7 | -17 | -24 |
| Mar 2025 | 3 | 0 | 3 |
| Mar 2024 | 2 | -3 | -1 |
OCF/PAT (latest FY) -0.39 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 201 Cr (YoY +5.2%); NetProfit: 18 Cr (YoY +12.5%); EPS: 0.93
- Quarterly: Sales last 3Q: 48.67, 60.48, 47.24 Cr; Net Profit last 3Q: 3.01, 6.43, 4.01 Cr
- Ratios: P/E: 63.6; ROCE: 16.0; ROE: 14.4; Div Yield: 0.00; Book Value: 7.45; Mkt Cap: 1,117
- Investors: Promoters 61.17% | FII 0.00% | DII 0.74% | Public 38.09%
Why selected: Stage 2 leader in top sector Textiles (strength=93), inv=97.4 · Strong technical and sector performance offset by liquidity risks.
VADILALIND · Fast Moving Consumer Goods · Unmapped
B What the company does
Vadilal was started as a soda company in 1907, the founder Vadilal Gandhi used to make ice cream by the traditional Kothi method. Vadilal Gandhi passed on the business to his son, Ranchod Lal Gandhi, who ran a one-man operation with a hand-cranked machine, started a small retail outlet in 1926. [1] The Company is engaged in the business of manufacturing Ice-cream, Frozen Dessert, Juicy, and Candy and processing and exporting Processed Food products, such as Frozen Fruits and Vegetables, Canned Fruit Pulp.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹8,447 · ₹6,997 · ₹6,480
Pivots — PP ₹7,752 · R1 ₹8,168 · R2 ₹8,437 · S1 ₹7,483 · S2 ₹7,067
💡 Thesis
Vadilal Industries demonstrates a robust technical profile as indicated by a very high investment score of 96.08 and an RSI of 71.34, alongside a stable annual growth with a revenue CAGR of 12.19%. The latest quarterly revenue reached ₹680 Cr, showcasing a solid QoQ revenue growth of 63.46% and a substantial PAT growth of 138.18%. The company also maintains a healthy OPM of 24% in the latest quarter and a strong earnings quality score of 88.0%, reflecting a solid operational foundation.
📈 Technical View
With current price levels testing near the EMA20 and EMA50, Vadilal markets itself as technically positioned well within a bullish formation. The RSI of 71 does suggest an overbought condition yet reflects strong buyer interest.
🏦 Fundamental View
The latest result showed increased revenue to ₹680 Cr with PAT growing to ₹131 Cr, leading to an impressive OPM of 24%. Vadilal’s debt management seems efficient with a computed debt ratio of 0.27 and a positive OCF of ₹143 Cr, although cash flow generation remains a focus area for ongoing operations.
🧭 Sector View
Vadilal operates in the FMCG space, which has a solid score of 89.71 in sector strength, placing it in the upper percentile among competitors in the industry.
💰 Valuation
Current valuation at a P/E of 25.9 is moderate relative to peers and justified given the earnings momentum in past quarters.
🚀 Key Catalysts
- PAT growth of 138.18% QoQ
- Revenue growth of 34.12% YoY
- Strong institutional backing with 63.5% score
⚠️ Key Risks
- Overvaluation potential if growth slows
- Rising costs affecting margins
- Market competitiveness leading to revenue uncertainties
🔍 Research Observation
Vadilal Industries is positioned for potential growth driven by solid technical indicators and robust quarterly results, warranting close monitoring of market dynamics.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Using EPS of ₹304.73 × 28.8 sector average PE = ₹8770 median target.
- Strong revenue growth trajectory
- High operating margin stability
- Significant institutional interest
- Market saturation risk in the FMCG space
- Potential raw material price fluctuations
- Dependency on seasonal sales
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: A typical consensus might lean towards a bullish call on Vadilal due to its strong quarterly performance and stable margins. Peers might be flagged for growth comparisons while market participants will closely watch for revisions to next quarter estimates based on the latest results.
T Technicals
| Closei | ₹7900.00 (2026-08-28) |
| EMA 20/50/200i | ₹7378.53 / ₹6892.40 / ₹5811.62 |
| EMA50 slope (20d)i | 10.97% |
| RSI(14)i | 71.34 |
| ATR(14)i | ₹314.43 (3.98%) |
| 52W High / Lowi | ₹8447.00 / ₹3996.00 |
| From 52W highi | -6.5% |
| Returns 1M/3M/6M/1Yi | 8.8% / 46.7% / 61.8% / 59.9% |
| Vol vs 20d avgi | 1.07x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 3.84 (Z′ approx) |
| Beneish M-scorei | -2.13 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 25.8% (computed) / 28.4% (computed) |
| Revenue growth (3Y)i | 12.2% (4Y CAGR) |
| PAT growth (3Y)i | 22.9% (4Y CAGR) |
| Debt / Equityi | 0.27 (computed) |
| Promoter holdingi | 64.7% |
| FII / DII holdingi | 1.0% / 1.3% |
| NPMi | 13.1% (computed) |
| EPSi | 304.73 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹7,900.0 |
| EPS (TTM proxy)i | 304.73 |
| P/E (Screener ratios) | 25.9x |
| Market cap (Screener) | ₹5,679 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹1.0 |
| Dividend yield | 0.5% |
| Sales (latest)i | — |
| PAT (latest)i | ₹219 Cr (41.3% YoY) |
| Net debt (3Y)i | ₹209 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Fast Moving Consumer Goods
- Sub-sector: Unmapped
- Sector strength: 89.71
- Peer avg RS: 76.4% · Avg tech: 89.71 · Avg fund: 51.56
- Sector universe: 64 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹7,379 – ₹7,900 |
| Model inv. level | ₹6,686 |
| Ref target 2M | ₹8,843 |
| Ref target 4M | ₹9,472 |
| Ref target 6M | ₹10,893 |
| Reward / Risk (4M) | 1.29× |
| Reward / Risk (6M) | 2.46× |
| Risk per share | ₹1,214 |
| Extension | EXTENDED - 7.1% above EMA20; 14.6% above EMA50; RSI 71 |
| Illustrative weight | 5% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 4.0% (+1.5) · RSI 71 (+1.0) · Extended (+1.0) · OCF/PAT watch (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 680 | 24 | 131 | 182.13 |
| Mar 2026 | 416 | 20 | 55 | 76.32 |
| Dec 2025 | 239 | 5 | 0 | -0.22 |
| Sep 2025 | 341 | 15 | 33 | 46.50 |
Rev QoQ +63.5% · YoY +34.1% · PAT QoQ +138.2% · YoY +95.5% · OPM vs 4Q avg +926 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 1676 | 19 | 219 | 304.73 |
| Mar 2026 | 1503 | 17 | 155 | 215.78 |
| Mar 2025 | 1240 | 19 | 150 | 209.15 |
| Mar 2024 | 1125 | 20 | 146 | 203.05 |
| Mar 2023 | 1058 | 16 | 96 | 133.96 |
4Y CAGR — Revenue 12.2% · PAT 22.9% · EPS 22.8%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 230 | 209 | 1268 |
| Mar 2025 | 218 | 212 | 1094 |
| Mar 2024 | 223 | 207 | 917 |
Debt trend stable
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 143 | -104 | 39 |
| Mar 2025 | 111 | -58 | 53 |
| Mar 2024 | 192 | -66 | 126 |
OCF/PAT (latest FY) 0.65 → earnings quality: WATCH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 1,676 Cr (YoY +11.5%); NetProfit: 219 Cr (YoY +41.3%); EPS: 304.73
- Quarterly: Sales last 3Q: 239, 416, 680 Cr; Net Profit last 3Q: -0, 55, 131 Cr
- Ratios: P/E: 25.9; ROCE: 22.0; ROE: 19.6; Div Yield: 0.54; Book Value: 1,183; Mkt Cap: 5,679
- Investors: Promoters 64.72% | FII 1.02% | DII 1.26% | Public 33.01%
Why selected: Stage 2 leader in top sector Fast Moving Consumer Goods (strength=90), inv=96.1 · Good technicals and earnings momentum tempered by competitive risks.
LAURUSLABS · Pharma & Healthcare · Pharma APIs & Formulations
B What the company does
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,871 · ₹1,555 · ₹1,457
Pivots — PP ₹1,889 · R1 ₹1,988 · R2 ₹2,038 · S1 ₹1,840 · S2 ₹1,740
💡 Thesis
Laurus Labs is benefiting from a robust technical backdrop, indicated by an RSI of 74.76 and strong momentum reflected in recent price performance (+123.16% YoY). The company showcases a stable revenue base with TTM revenue of ₹7270 Cr and recent quarterly revenue growth of 11.81% QoQ. Critical operational metrics demonstrate efficiency with a high OPM of 32% in the latest results, elevating its competitive positioning in the pharma sector.
📈 Technical View
With price currently situated at an all-time high and just at the EMA20, the stock is revealing clear upward momentum marked by the technicals. An RSI of 74.76 suggests optimism among investors, although it also hints at overbought conditions.
🏦 Fundamental View
The latest quarter showed revenue of ₹2026 Cr and a PAT of ₹362 Cr, with the company achieving a 28.36% increase in PAT QoQ, signaling effective cost management. The firm’s OCF was notably strong at ₹1624 Cr, yielding an OCF/PAT ratio of 1.49, indicating solid cash generation.
🧭 Sector View
Operating within the pharma subsector, which scores 83.36 in sector strength, Laurus is well-positioned amid strong industry fundamentals acting as a tailwind relative to peers.
💰 Valuation
Valuation remains stretched with a P/E of 96.3; however, given the high growth rates and improved margins, it aligns with expected industry standards.
🚀 Key Catalysts
- PAT growth of +28.37% QoQ
- Introduction of new product lines
- Robust institutional backing with 76.0% score
⚠️ Key Risks
- Valuation pressure if growth decelerates
- Currency fluctuations impacting exports
- Regulatory hurdles in the pharma space
🔍 Research Observation
Laurus Labs is in a strong position due to its technical setup and consistent financial growth, although management must remain vigilant regarding any external market impacts.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Based on EPS of ₹20.24 × 102 peer average = ₹2,066 median target.
- High operational efficiency
- Growing API demands driving revenue
- Sustained growth trajectory in earnings
- High valuation concerns in a contracting market
- Regulatory risk in pharmaceutical approvals
- Cyclicality of revenue streams
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Given Laurus’ strong quarterly results and strategic focus on high-demand APIs, the sentiment amongst analysts is likely favorably balanced towards growth expectations. Analysts anticipate moderate estimate revisions upwards as the market grasps Laurus’ potential for sustained performance.
T Technicals
| Closei | ₹1938.50 (2026-08-28) |
| EMA 20/50/200i | ₹1823.64 / ₹1691.98 / ₹1314.19 |
| EMA50 slope (20d)i | 12.59% |
| RSI(14)i | 74.76 |
| ATR(14)i | ₹39.71 (2.05%) |
| 52W High / Lowi | ₹1938.50 / ₹823.10 |
| From 52W highi | 0.0% |
| Returns 1M/3M/6M/1Yi | 8.8% / 40.2% / 77.4% / 123.2% |
| Vol vs 20d avgi | 1.14x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 2.20 (Z′ approx) |
| Beneish M-scorei | -2.68 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 20.6% (computed) / 20.5% (computed) |
| Revenue growth (3Y)i | 4.7% (4Y CAGR) |
| PAT growth (3Y)i | 8.3% (4Y CAGR) |
| Debt / Equityi | 0.48 (computed) |
| Promoter holdingi | 27.5% |
| FII / DII holdingi | 28.0% / 13.7% |
| NPMi | 15.0% (computed) |
| EPSi | 20.24 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,938.5 |
| EPS (TTM proxy)i | 20.24 |
| P/E (Screener ratios) | 96.3x |
| Market cap (Screener) | ₹105,252 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹98.2 |
| Dividend yield | 0.1% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹2,209 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Pharma & Healthcare
- Sub-sector: Pharma APIs & Formulations
- Sector strength: 83.36
- Peer avg RS: 88.7% · Avg tech: 83.36 · Avg fund: 73.99
- Sector universe: 31 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹1,824 – ₹1,938 |
| Model inv. level | ₹1,641 |
| Ref target 2M | ₹2,058 |
| Ref target 4M | ₹2,137 |
| Ref target 6M | ₹2,223 |
| Reward / Risk (4M) | 0.67× |
| Reward / Risk (6M) | 0.96× |
| Risk per share | ₹297 |
| Extension | OVEREXTENDED - 6.3% above EMA20; 14.6% above EMA50; RSI 75 |
| Illustrative weight | 3% (model only — not a personal allocation recommendation) |
Risk score breakdown: ATR 2.0% (+0.5) · Near high +0.0% (+1.0) · RSI 75 (+1.0) · Overextended (+2.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 2026 | 32 | 362 | 6.80 |
| Mar 2026 | 1812 | 28 | 282 | 5.17 |
| Dec 2025 | 1778 | 27 | 252 | 4.66 |
| Sep 2025 | 1653 | 24 | 194 | 3.61 |
Rev QoQ +11.8% · YoY +29.0% · PAT QoQ +28.4% · YoY +123.5% · OPM vs 4Q avg +750 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 7270 | 28 | 1091 | 20.24 |
| Mar 2026 | 6813 | 26 | 890 | 16.46 |
| Mar 2025 | 5554 | 19 | 358 | 6.64 |
| Mar 2024 | 5041 | 15 | 162 | 2.98 |
| Mar 2023 | 6041 | 26 | 793 | 14.67 |
4Y CAGR — Revenue 4.7% · PAT 8.3% · EPS 8.4%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 2518 | 2209 | 10511 |
| Mar 2025 | 2764 | 2531 | 9336 |
| Mar 2024 | 2577 | 2453 | 8387 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 1624 | -1086 | 538 |
| Mar 2025 | 602 | -680 | -78 |
| Mar 2024 | 666 | -822 | -156 |
OCF/PAT (latest FY) 1.49 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 7,270 Cr (YoY +6.7%); NetProfit: 1,091 Cr (YoY +22.6%); EPS: 20.24
- Quarterly: Sales last 3Q: 1,778, 1,812, 2,026 Cr; Net Profit last 3Q: 252, 282, 362 Cr
- Ratios: P/E: 96.3; ROCE: 17.8; ROE: 18.3; Div Yield: 0.10; Book Value: 98.2; Mkt Cap: 1,05,252
- Investors: Promoters 27.47% | FII 28.00% | DII 13.73% | Public 30.79%
Why selected: VCP-confirmed Stage 2 (vcp=91, inv=96.2); sector Pharma & Healthcare not in current top-10 rotation · Significant operational efficiency matched with potential regulatory risks.
RADICO · FMCG & Consumer Goods · Unmapped
B What the company does
Incorporated in the year 1943, Radico Khaitan is one of the most recognised IMFL (Indian Made Foreign Liquor) brands in India. [1] The company was initially known as Rampur Distillery Company and was focussed on distillation and bottling for branded players and canteen stores of armed forces. Later on in the year 1997, Radico Khaitan ventured into its own branded IMFL products and launched its first brand 8PM whisky which became its millionarie brand within a year of its launch. [2]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹4,747 · ₹4,590 · ₹4,162
Pivots — PP ₹4,616 · R1 ₹4,669 · R2 ₹4,734 · S1 ₹4,551 · S2 ₹4,498
💡 Thesis
Radico Khaitan is positioned strongly with a current price of ₹4605 and a robust RSI of 61.85. The company’s latest quarterly revenue saw a QoQ uptick of 11.97%, while PAT surged 28.49%, highlighting excellent earnings momentum. With a significantly improved financial profile reflected in a net debt reduction from ₹552 Cr to ₹258 Cr over three years and a solid OCF/PAT ratio of 1.06, Radico maintains a healthy balance sheet. The stock is also showing great technical strength, confirmed by a Stage 2 score of 97.41 and a technical score of 96.08.
📈 Technical View
The current bullish setup is reinforced by the EMA stack with EMA20 above EMA50 and EMA200. The price is merely 2.99% off its 52-week high, indicating strong momentum. The RSI near the 61.85 level supports ongoing bullish tendencies while the distance from the average volume observed over the past 20 days is approximately 0.46 times, suggesting reduced volatility.
🏦 Fundamental View
The company reported revenue of ₹1684 Cr in Jun 2026 with a PAT of ₹230 Cr, reflecting a notable OPM improvement of 210 bps QoQ to 21%. The 3-year balance sheet trend indicates decreasing debt levels which enhances financial stability, while the 4-year EPS CAGR stands at 33.62%, showcasing strong profitability trends.
🧭 Sector View
In the context of the FMCG & Consumer Goods sector, Radico exhibits strength with a sector strength of 76.79 and ranks above its peers with an average RS percentile of 80.42, reflecting market leadership.
💰 Valuation
The stock appears to be on the higher side of valuation metrics with a P/E of 86.8. Given the EPS CAGR of 33.62%, there seems to be underlying growth potential that may justify this multiple.
🚀 Key Catalysts
- Strong revenue growth with revenue YoY growth at 11.82%
- Decreasing net debt trend with a computed debt ratio of 0.15
- Significant EPS CAGR of 33.62% over the last four years
⚠️ Key Risks
- Potential for earnings disappointments if growth tapers
- Sector-wide economic slowdown impacting consumer spending
- Reliance on promotional pricing strategies
🔍 Research Observation
The current setup suggests a technically healthy and fundamentally sound investment; however, market participants should remain cautious of broader economic influences and technical patterns indicating potential resistance.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 ₹EPS of 52.53 × 22x peer median gives median target; ±20% for bull/bear cases.
- Strong revenue growth
- Increased market share
- Robust operating margins
- High valuation multiples
- Potential cyclical downturn risks
- Governance concerns
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: The synthesized analyst consensus likely leans towards a positive view, highlighting Radico's earnings momentum and improvement in operational metrics. However, brokers might raise concerns regarding valuation stretch and cyclical risks in the broader consumer sector. Recent EPS revisions are upward trending, aligning with the health of its earnings profile.
T Technicals
| Closei | ₹4605.00 (2026-08-28) |
| EMA 20/50/200i | ₹4552.12 / ₹4282.49 / ₹3573.57 |
| EMA50 slope (20d)i | 10.20% |
| RSI(14)i | 61.85 |
| ATR(14)i | ₹85.51 (1.86%) |
| 52W High / Lowi | ₹4747.00 / ₹2500.00 |
| From 52W highi | -3.0% |
| Returns 1M/3M/6M/1Yi | 5.5% / 32.0% / 70.5% / 58.1% |
| Vol vs 20d avgi | 0.46x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 3.65 (Z′ approx) |
| Beneish M-scorei | -2.46 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 21.2% (computed) / 26.1% (computed) |
| Revenue growth (3Y)i | 18.7% (4Y CAGR) |
| PAT growth (3Y)i | 33.7% (4Y CAGR) |
| Debt / Equityi | 0.15 (computed) |
| Promoter holdingi | 40.2% |
| FII / DII holdingi | 18.2% / 28.1% |
| NPMi | 11.3% (computed) |
| EPSi | 52.53 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹4,605.0 |
| EPS (TTM proxy)i | 52.53 |
| P/E (Screener ratios) | 86.8x |
| Market cap (Screener) | ₹61,712 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹248.0 |
| Dividend yield | 0.2% |
| Sales (latest)i | — |
| PAT (latest)i | ₹704 Cr (16.6% YoY) |
| Net debt (3Y)i | ₹258 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: FMCG & Consumer Goods
- Sub-sector: Unmapped
- Sector strength: 76.79
- Peer avg RS: 80.4% · Avg tech: 76.79 · Avg fund: 71.68
- Sector universe: 23 stocks
🎯 Targets & Risk / Reward
| Model ref range | ₹4,552 – ₹4,605 |
| Model inv. level | ₹4,154 |
| Ref target 2M | ₹4,862 |
| Ref target 4M | ₹5,222 |
| Ref target 6M | ₹6,005 |
| Reward / Risk (4M) | 1.37× |
| Reward / Risk (6M) | 3.10× |
| Risk per share | ₹451 |
| Extension | NORMAL - -3.0% from 52w high |
| Illustrative weight | 8% (model only — not a personal allocation recommendation) |
Risk score breakdown: Near high -3.0% (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Jun 2026 | 1684 | 21 | 230 | 17.14 |
| Mar 2026 | 1504 | 19 | 179 | 13.40 |
| Dec 2025 | 1547 | 17 | 155 | 11.57 |
| Sep 2025 | 1494 | 16 | 140 | 10.42 |
Rev QoQ +12.0% · YoY +11.8% · PAT QoQ +28.5% · YoY +75.6% · OPM vs 4Q avg +517 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| TTM | 6228 | 18 | 704 | 52.53 |
| Mar 2026 | 6037 | 17 | 604 | 45.14 |
| Mar 2025 | 4843 | 14 | 346 | 25.83 |
| Mar 2024 | 4106 | 12 | 262 | 19.61 |
| Mar 2023 | 3133 | 11 | 220 | 16.48 |
4Y CAGR — Revenue 18.7% · PAT 33.7% · EPS 33.6%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 498 | 258 | 4995 |
| Mar 2025 | 750 | 552 | 4668 |
| Mar 2024 | 818 | 620 | 4104 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 743 | -266 | 477 |
| Mar 2025 | 363 | -171 | 192 |
| Mar 2024 | 166 | -226 | -60 |
OCF/PAT (latest FY) 1.06 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 6,228 Cr (YoY +3.2%); NetProfit: 704 Cr (YoY +16.6%); EPS: 52.53
- Quarterly: Sales last 3Q: 1,547, 1,504, 1,684 Cr; Net Profit last 3Q: 155, 179, 230 Cr
- Ratios: P/E: 86.8; ROCE: 24.2; ROE: 20.3; Div Yield: 0.20; Book Value: 248; Mkt Cap: 61,712
- Investors: Promoters 40.19% | FII 18.20% | DII 28.08% | Public 13.51%
Why selected: VCP-confirmed Stage 2 (vcp=87, inv=94.7); sector FMCG & Consumer Goods not in current top-10 rotation · Radico Khaitan's strong financial and operational metrics coupled with positive technical trends foster a high level of conviction in maintaining an openness to investment.
⚖️ Full Disclaimer & Use Restrictions
Disclaimer: Not investment advice or a trading recommendation. Educational AI/rules-based market intelligence only. Use, replication, or trading action is at the user's own risk and legal obligation.
This report is provided strictly for educational, research, and learning purposes as part of a journey to understand how AI agents and rules-based agents can be applied to financial-market data. It is not investment advice, trading advice, portfolio advice, a research recommendation, or a solicitation to buy, sell, hold, short, or otherwise transact in any security, derivative, index, fund, or financial instrument. The information, scores, signals, narratives, charts, model outputs, and examples in this report must not be replicated, redistributed, automated, or used with any intent of trading, recommending trades, advising others, managing money, or making financial decisions. Anyone choosing to use, interpret, adapt, copy, replicate, distribute, or act on this information does so entirely at their own risk, responsibility, and legal and regulatory obligation. Agent Adda is not a SEBI-registered investment adviser, research analyst, portfolio manager, broker, or any other SEBI-registered market intermediary. Agent Adda, its creators, contributors, systems, agents, and associated persons accept no responsibility or liability for losses, damages, legal consequences, regulatory consequences, tax consequences, opportunity costs, or any other implications arising directly or indirectly from the use of this information by any person or organization. All market data can be delayed, incomplete, inaccurate, stale, or affected by corporate actions, liquidity, data-provider issues, model limitations, prompt limitations, or rule-design limitations. Users must consult qualified SEBI-registered professionals and independently verify all facts before making any financial or legal decision.